biologic

Zinplava

bezlotoxumab

Loss of exclusivityOctober 2028projected — 12-year biologic exclusivity estimate
CompanyMerck Sharp & Dohme LLC

Drug detail

Brand nameZinplava
Active ingredientbezlotoxumab
Strength1,000MG/40ML (25MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalOctober 2016
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.